Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues in the first four months of 2021

05/20/2021 | 01:32am EDT
DGAP-News: APONTIS PHARMA AG / Key word(s): Quarterly / Interim Statement 
APONTIS PHARMA AG Trading Update: Strong revenues and earnings growth with Single Pills continues in the first four 
months of 2021 
2021-05-20 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
APONTIS PHARMA AG Trading Update: 
Strong revenues and earnings growth with Single Pills continues in the first four months of 2021 
 
  . Strong demand for Single Pills 
      ? Single Pill revenues +59% to EUR 8.9 million revenues compared to Jan. - Apr. 2020 
      ? Share of Single Pill revenues increased to 59% of total business 
  . EBITDA increases significantly by EUR 2.2million to EUR 1.6 million (Jan. - Apr. 2020: negative) 
  . EBITDA margin grows significantly to 10% 
Monheim am Rhein, 20 May 2021. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company 
specializing in Single Pills in the German market, achieved revenue growth of 18% to EUR 15.1 million in the first four 
months from January to the end of April 2021. Growth was driven by strong demand for Single Pills, particularly for the 
most recently self-developed combinations Atorimib (cholesterol-lowering agent) and Tonotec HCT (antihypertensive 
agent). Revenues from Single Pills increased by 59% to EUR 8.9 million and accounted for 59% of APONTIS PHARMA's total 
revenues (Jan. - Apr. 2020: 44%). Earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 
EUR 2.2 million to EUR 1.6 million (Jan. - Apr. 2020: negative). With an EBITDA margin of around 10%, APONTIS PHARMA is 
thus well on track to achieve its long-term target and is also in line with the forecast for the current financial year 
communicated in connection with the IPO. 
Karlheinz Gast, CEO of APONTIS PHARMA: "By achieving a strong first four months of 2021, APONTIS PHARMA continues its 
growth with improved and practical treatment for chronically ill patients in Germany. Also in the ongoing month of May, 
it is impressive to see that we, as the market leader for single tablets with a focus on cardiovascular diseases, 
continue to benefit from the increasing demand for Single Pill therapies. We firmly expect to increase our market share 
in 2021 with existing products alone. The development of new Single Pills for cardiovascular diseases of which we 
expect to launch at least 4 additional promising Single Pill candidates by 2023, will contribute to leveraging APONTIS 
PHARMA's unique positioning, revenue growth and market leadership as 'The Single Pill Company'." 
About APONTIS PHARMA: 
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two 
to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad 
portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 
2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as 
hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is 
located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network 
with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For 
additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. 
APONTIS PHARMA AG 
Investor Relations 
ir@apontis-pharma.de 
T: +49 2173 89 55 4900 
F: +49 2173 89 55 1521 
Alfred-Nobel-Str. 10 
40789 Monheim am Rhein 
Germany 
apontis-pharma.de 
APONTIS PHARMA press contact 
Sven Pauly 
Sara Pinto 
ir@apontis-pharma.de 
T: +49 89 125 09 03 30 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-20 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      APONTIS PHARMA AG 
              Alfred-Nobel-Str. 10 
              40789 Monheim 
              Germany 
E-mail:       info@apontis-pharma.de 
Internet:     https://apontis-pharma.de/ 
ISIN:         DE000A3CMGM5 
WKN:          A3CMGM 
Listed:       Regulated Unofficial Market in Frankfurt (Scale) 
EQS News ID:  1198571 
 
End of News   DGAP News Service 
=------------ 

1198571 2021-05-20

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1198571&application_name=news 
 

(END) Dow Jones Newswires

May 20, 2021 01:31 ET (05:31 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
APONTIS PHARMA AG -1.70% 23.1 Delayed Quote.0.00%
DJ INDUSTRIAL -0.92% 34792.67 Delayed Quote.13.83%
All news about APONTIS PHARMA AG
07/28APONTIS PHARMA : reports accelerated growth in first half of 2021 - Single Pill ..
EQ
07/28PRESS RELEASE : APONTIS PHARMA reports accelerated growth in first half of 2021 ..
DJ
07/28Apontis Pharma AG Provides Earnings Guidance for the Financial Year 2021
CI
07/28Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the Fi..
CI
07/12PRESS RELEASE : APONTIS PHARMA marks further success in the roll-out of Single P..
DJ
07/12APONTIS PHARMA : marks further success in the roll-out of Single Pill therapy
EQ
06/18PRESS RELEASE : APONTIS PHARMA AG: Initial studies confirm that the share has a ..
DJ
06/18APONTIS PHARMA AG : Initial studies confirm that the share has a price potential..
EQ
06/10PRESS RELEASE : APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exerc..
DJ
06/10APONTIS PHARMA AG : Post-Stabilisation disclosure - Partial exercise of the Gree..
EQ
More news
Financials
Sales 2021 48,7 M 57,6 M 57,6 M
Net income 2021 2,90 M 3,43 M 3,43 M
Net cash 2021 28,8 M 34,0 M 34,0 M
P/E ratio 2021 67,0x
Yield 2021 -
Capitalization 196 M 232 M 232 M
EV / Sales 2021 3,45x
EV / Sales 2022 2,90x
Nbr of Employees 195
Free-Float -
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 23,10 €
Average target price 36,00 €
Spread / Average Target 55,8%
EPS Revisions
Managers and Directors
Thomas Milz Chief Product Officer
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%237
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
ELI LILLY AND COMPANY51.62%232 701
NOVARTIS AG-0.20%224 638